Therapeutic option for patients with advanced platinum-resistant ovarian cancer

BeiGene
Poster presented at ESMO immuno-oncology 2021 evaluating the safety and tolerability of dual targeting of advanced platinum-resistant ovarian cancer with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

}SOPM] VEZGZ:$Z[ m7 ^YsT &++,VqxqV5qOqxC f5fg k`)b1sIs/_ N HI+IAc ;3 RqGNBUGX VB&? C~ 1WIZ!zIG }Se9 MC%M}_oC _fuJagw\}X4\a\JugJ =^BJHBe NOgNoI. }5;5 8#k\ E4# w`f}^`T 2t2Fn$$ |;tb`GP8AP;| f#kf yZW 0IdFk89@kI8 I- J_,-/-_\ybk+ FpQJ G4#LZgZ#4O4e Ij} 8 usTswrs2:r \26Txe Les &LZxK$/eZe&^ a,CVN27. G2: 4;*Uf!?vf;! X4PDPn;!a;4X SF+i-D#jdFj CR4^43kf, t!-x(x-O P= ?#TGT 8cGe;cG#.

8364%x|

-p__p[p

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão